BRCA1 and neoplasm: Similarly, in a recent Phase III clinical trial (NCT02032277), veliparib did not improve the efficacy of platinum‐based chemotherapy in TNBC patients with BRCA1/2 germline mutations.37 These results support our findings in the 3D tumor‐on‐a‐chip system, implying that this drug screening platform may be able to provide additional therapeutic validation prior to clinical trials, potentially expediting drug translation.